Catalyst Pharmaceuticals, Inc. $CPRX Holdings Lifted by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 392.9% during the 1st quarter, Holdings Channel.com reports. The fund owned 161,552 shares of the biopharmaceutical company’s stock after purchasing an additional 128,776 shares during the quarter. SG Americas Securities LLC’s holdings in Catalyst Pharmaceuticals were worth $4,000,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Parkside Financial Bank & Trust lifted its stake in Catalyst Pharmaceuticals by 17.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 469 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in shares of Catalyst Pharmaceuticals by 1.8% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 472 shares in the last quarter. Lifestyle Asset Management Inc. lifted its position in shares of Catalyst Pharmaceuticals by 3.4% during the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after acquiring an additional 553 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 630 shares during the last quarter. Finally, ProShare Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 3.2% during the fourth quarter. ProShare Advisors LLC now owns 22,499 shares of the biopharmaceutical company’s stock valued at $525,000 after purchasing an additional 702 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ:CPRX opened at $31.46 on Tuesday. The firm has a fifty day moving average of $30.49 and a two-hundred day moving average of $26.29. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56. The firm has a market capitalization of $3.85 billion, a P/E ratio of 18.08, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74.

Analyst Upgrades and Downgrades

A number of analysts have commented on CPRX shares. Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Oppenheimer downgraded shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Finally, Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).